FDA NDA · NDA214094

ORLADEYO

berotralstat hydrochloride

Sponsor: BIOCRYST

What this page does not claim

A drug page is a reference view of public FDA data (Drugs@FDA), reproduced as published. SPEQ is not affiliated with the FDA, adds no interpretation to the record, and nothing here is medical, legal, or regulatory advice.

APPLICATION
NDA214094
TYPE
NDA
ORIGINAL APPROVAL
2020-12-03
LATEST ACTION
2026-10-16
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Prescription

Products

ORLADEYO · ReferencePrescription
BEROTRALSTAT DIHYDROCHLORIDE EQ 150MG BASE · CAPSULE · ORAL
ORLADEYO · ReferencePrescription
BEROTRALSTAT DIHYDROCHLORIDE EQ 110MG BASE · CAPSULE · ORAL

Approval history

2026-10-16Labeling · Supplement 6 · standard — Label ↗AP
2025-12-23Labeling · Supplement 5 · standard — Letter ↗AP
2024-10-21Labeling · Supplement 3 · standard — Letter ↗AP
2023-11-21Labeling · Supplement 2 · standard — Label ↗AP
2020-12-03Type 1 - New Molecular Entity · Original · standard — Letter ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. Browse every approval SPEQ tracks →